SKSimon Karpatkin

Simon Karpatkin

*This is an algorithmically generated author record based on publicly available information.

Simon Karpatkin has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Jian-Jun Li

    From the New York University Medical Center and Kaplan Cancer Center, New York, NY; the Department of Veterans Affairs Medical Center, New York, NY; and the R.W. Johnson Pharmaceutical Research Institute, Spring House, PA

    2 shared publications
  • Kenichi Takeshita

    From the New York University Medical Center and Kaplan Cancer Center, New York, NY; the Department of Veterans Affairs Medical Center, New York, NY; and the R.W. Johnson Pharmaceutical Research Institute, Spring House, PA

    2 shared publications
  • Kui Chen

    From the New York University Medical Center and Kaplan Cancer Center, New York, NY; the Department of Veterans Affairs Medical Center, New York, NY; and the R.W. Johnson Pharmaceutical Research Institute, Spring House, PA

    2 shared publications
  • Mary Lynn Nierodzik

    From the New York University Medical Center and Kaplan Cancer Center, New York, NY; the Department of Veterans Affairs Medical Center, New York, NY; and the R.W. Johnson Pharmaceutical Research Institute, Spring House, PA

    2 shared publications
  • Michael R. D’andrea

    From the New York University Medical Center and Kaplan Cancer Center, New York, NY; the Department of Veterans Affairs Medical Center, New York, NY; and the R.W. Johnson Pharmaceutical Research Institute, Spring House, PA

    2 shared publications
  • Patricia Andrade-Gordon

    From the New York University Medical Center and Kaplan Cancer Center, New York, NY; the Department of Veterans Affairs Medical Center, New York, NY; and the R.W. Johnson Pharmaceutical Research Institute, Spring House, PA

    2 shared publications

Latest Publications

  • Open Access

    Protease-Activated Receptor 1 (PAR-1) Is Required and Rate-Limiting for Thrombin-Enhanced Experimental Pulmonary Metastasis

    by Mary Lynn Nierodzik, Kui Chen, Kenichi Takeshita, Jian-Jun Li, Yao-Qi Huang, Xue-Sheng Feng, Michael R. D’andrea, Patricia Andrade-Gordon, Simon Karpatkin

    Thrombin-treated tumor cells induce a metastatic phenotype in experimental pulmonary murine metastasis. Thrombin binds to a unique protease-activated receptor (PAR-1) that requires N-terminal proteolytic cleavage for activation by its tethered end. A 14-mer thrombin receptor activation peptide (TRAP) of the tethered end induces the same cellular changes as thrombin. Four murine tumor cells (Lewis lung, CT26 colon CA, B16F10 melanoma, and CCL163 fibroblasts) contain PAR-1, as detected by reverse transcriptase-polymerase chain reaction (RT-PCR). B16F10 cells did not contain the two other thrombin receptors, PAR-3 and glycoprotein Ib. TRAP-treated B16F10 tumor cells enhance pulmonary metastasis 41- to 48-fold (n = 17). Thrombin-treated B16F10 cells transfected with full-length murine PAR-1 sense cDNA (S6, S7, S14, and S22) enhanced their adhesion to fibronectin 1.5- to 2.4-fold (n = 5, P < .04), whereas thrombin-treated wild-type cells do not. S6 (adhesion index, 1.5-fold) and S14 (index, 2.4-fold) when examined by RT-PCR and Northern analysis showed minimal expression of PAR-1 for S6 over wild-type and considerable expression for S14. Immunohistochemistry showed greater expression of PAR-1 for S14 compared with wild-type or empty-plasmid transfected cells. In vivo experiments with the thrombin-treated S14 transfectant showed a fivefold to sixfold increase in metastases compared with empty-plasmid transfected thrombin-treated naive cells or S6 cells (n = 20, P = .0001 to .02). Antisense had no effect on thrombin-stimulated tumor mass. Thus, PAR-1 ligation and expression enhances and regulates tumor metastasis.


  • Open Access

    Protease-Activated Receptor 1 (PAR-1) Is Required and Rate-Limiting for Thrombin-Enhanced Experimental Pulmonary Metastasis

    by Mary Lynn Nierodzik, Kui Chen, Kenichi Takeshita, Jian-Jun Li, Yao-Qi Huang, Xue-Sheng Feng, Michael R. D’andrea, Patricia Andrade-Gordon, Simon Karpatkin

    Thrombin-treated tumor cells induce a metastatic phenotype in experimental pulmonary murine metastasis. Thrombin binds to a unique protease-activated receptor (PAR-1) that requires N-terminal proteolytic cleavage for activation by its tethered end. A 14-mer thrombin receptor activation peptide (TRAP) of the tethered end induces the same cellular changes as thrombin. Four murine tumor cells (Lewis lung, CT26 colon CA, B16F10 melanoma, and CCL163 fibroblasts) contain PAR-1, as detected by reverse transcriptase-polymerase chain reaction (RT-PCR). B16F10 cells did not contain the two other thrombin receptors, PAR-3 and glycoprotein Ib. TRAP-treated B16F10 tumor cells enhance pulmonary metastasis 41- to 48-fold (n = 17). Thrombin-treated B16F10 cells transfected with full-length murine PAR-1 sense cDNA (S6, S7, S14, and S22) enhanced their adhesion to fibronectin 1.5- to 2.4-fold (n = 5, P < .04), whereas thrombin-treated wild-type cells do not. S6 (adhesion index, 1.5-fold) and S14 (index, 2.4-fold) when examined by RT-PCR and Northern analysis showed minimal expression of PAR-1 for S6 over wild-type and considerable expression for S14. Immunohistochemistry showed greater expression of PAR-1 for S14 compared with wild-type or empty-plasmid transfected cells. In vivo experiments with the thrombin-treated S14 transfectant showed a fivefold to sixfold increase in metastases compared with empty-plasmid transfected thrombin-treated naive cells or S6 cells (n = 20, P = .0001 to .02). Antisense had no effect on thrombin-stimulated tumor mass. Thus, PAR-1 ligation and expression enhances and regulates tumor metastasis.


  • GPIIIa-(49–66) is a major pathophysiologically relevant antigenic determinant for anti-platelet GPIIIa of HIV-1-related immunologic thrombocytopenia

    by Michael A. Nardi, Lin-Xing Liu, Simon Karpatkin

    High-affinity ( K d = 1 × 10 −9 M) anti-platelet GPIIIa has been isolated from serum immune complexes of immunologic thrombocytopenic HIV-1-infected patients (HIV-1-ITP). Affinity-purified anti-platelet antibody reacted with a recombinant GPIIIa-(1–200) and -(1–66) fusion peptide and with an 18-mer GPIIIa-(49–66) peptide but not with seven other GPIIIa peptides spanning the length of GPIIIa. Most of the anti-platelet antibody (≈85%) could be adsorbed to and eluted from a GPIIIa-(49–66) affinity column. Binding of antibody to platelets could be inhibited by GPIIIa-(49–66) or an equimolar peptide-albumin conjugate (IC 50 = 2 μM). Sera from 7 control subjects and 10 classic autoimmune thrombocytopenic patients gave background reactivity with GPIIIa-(49–66). HIV-1-ITP sera from 16 patients reacted with a mean OD 6-fold greater than background (range, 4- to 9-fold). Serum anti-GPIIIa-(49–66) concentration correlated inversely with platelet count, R 2 = 0.51, n = 31, P < 0.0001. Because mouse platelet GPIIIa-(49–66) has 83% homology with human GPIIIa and mouse monocytes contain Fc receptors for the human IgG1-κ/λ antibody, we determined the in vivo effect of human anti-GPIIIa on mouse platelets. Affinity-purified antibody, 25–50 μg given i.p., resulted in a precipitous drop in platelet count to 30% of baseline, with nadir at 4 hr and return to normal in 36 hr. No effect was noted with control IgG. Acute thrombocytopenia could be prevented or reversed by the injection of the GPIIIa-(49–66) albumin conjugate at zero time or 2 hr after antibody, respectively, but not with a scrambled peptide-albumin conjugate. Thus HIV-1-ITP patients have high-affinity anti-platelet GPIIIa against a major antigenic determinant, GPIIIa-(49–66), which correlates inversely with platelet count and induces thrombocytopenia in mice.


  • Open Access

    Autoimmune (idiopathic) thrombocytopenic purpura

    by Simon Karpatkin